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Abstract 
The diagnostic value of biomarkers of alcohol consumption differs dependent upon the population under investigation. In 
this regard, clarification is needed in the choice of biomarker used to aid the medical assessor support a return to driving 
after a drink-driving offence. Blood samples were collected (5mL serum and 3.5mL whole blood EDTA) to measure 
carbohydrate deficient transferrin (%CDT) as a biomarker of alcohol consumption compared to gamma glutamyl 
transferase (GGT), mean corpuscular volume (MCV), aspartate aminotransferase (AST), and alanine aminotransferase 
(ALT). Subjects were recruited to reflect the characteristics of a high-risk drink driving community in the United 
Kingdom. The ICD-10 or the Alcohol Use Disorders Identification Test (AUDIT) was used to diagnose an alcohol use 
disorder. 358 participants were recruited: 165 seeking treatment for harmful use or alcohol dependence: 142 seeking 
treatment for liver, diabetes or obesity problems: and 51 social drinkers (controls). %CDT was able to identify drinking 
indicative of excessive alcohol intake significantly more accurately than other biomarkers (Z=-9.017, p<0.001). The 
positive predictive value for %CDT (+ve PPV 0.88) demonstrated the best diagnostic power when tested compared to 
GGT (+ve PPV 0.69), inclusive of confounders. When the whole study population was taken into account the sensitivity 
and specificity of %CDT for the diagnosis of excessive alcohol use remained unchanged (area under curve 0.91) whereas 
the diagnostic power of GGT was poorer (area under curve 0.80). %CDT was superior to GGT as a marker of excessive 
alcohol consumption (continuous drinking) when tested against a population that included diabetic, obese and patients 
with non-alcoholic liver disease: a data set which bests mimics those seen in the high-risk drink driving population. 
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Introduction 
Driving a motor vehicle is a complex multifunctional 
task involving visual search and recognition, vigilance, 
information processing under variable demand, decision-
making, risk-taking and enough sensory-motor control to 
carry out all these activities correctly [1]. Driving has 
become a daily activity for most people in developed 
countries and although traffic accidents have many 
different causes, most cases involve human factors, the 
most common being ‘driving under the influence’ (DUI) of 
alcohol [2-4]. Large proportions of apprehended drivers 
are often repeat offenders and the prevalence of heavy 
drinkers is high amongst repeat offenders [5]. 
Identification of continuous drinking in high-risk drivers 
therefore has important traffic-safety, health, social, legal 
and economic ramifications for both the individual and 
society [6-10]. Owing to judicial issues, alcohol 
consumption is not always accurately reported and 
evidence of voluntarily under-reporting has been 
documented [11].  
  
Although biomarkers are often considered to be an 
objective, gauge of alcohol consumption [8,12,13] they 
vary in efficacy according to different parameters, the 
individual concerned and the collection site, such that a 
gold standard for the identification of continuous drinking 
has to date been elusive. The diagnostic sensitivity of 
biomarkers depends on the time since the last drink. 
Problematic alcohol consumption is usually diagnosed on 
the basis of clinical history; self-reported or collateral 
information about alcohol consumption and biomarker 
tests.  
  
Disqualified drink-drivers in the UK are placed on a 
high-risk offender scheme (HRO) and must attend an 
independent medical assessment for re-licensing. Four 
biomarkers are commonly used to aid assessment of 
continuous drinking in high risk drink-drivers: gamma 
glutamyl transferase (GGT); mean cell volume (MCV); 
aspartate aminotransferase (AST); and alanine 
aminotransferase (ALT). Problems exist in the 
interpretation of these biomarkers since medical and life-
style factors (non-alcoholic liver disease, smoking, excess 
body weight and low physical activity) are known to 
confound the test results [14]. Carbohydrate deficient 
transferrin (%CDT) has been identified as a potential 
alternative measure [15-19].  
 
In this study we sought to determine, the diagnostic 
efficacy (sensitivity and specificity) of %CDT compared to 
GGT, MCV, ALT and AST as a biomarker for the detection 
of continued alcohol consumption in sub-populations 
characteristic of those wishing to apply for a new license 
after a drink-driving offence.  
 
Materials and Methods 
The methods section includes participants, definitions, 
procedures, analysis of biomarkers and statistical 
analysis. 
 
Participants 
Participants were recruited from clinics for the 
treatment of alcohol problems (2 inpatient units for 
severely alcohol dependent individuals (unit 1 and 2) and 
2 specialist out-patient, drug and alcohol services (unit 3 
and 4) for those with problematic alcohol use) based at 
the South London & Maudsley NHS Foundation Trust 
(SLaM), London, UK. Patients were also recruited from 3 
distinct hospital populations within King’s College 
Hospital (KCH) NHS Foundation Trust, London to 
investigate the extent to which medical factors might 
confound the test results: unit 5 (the Institute of Liver 
Studies) a referral centre for hepatobiliary disease, 
autoimmune liver disease, viral hepatitis and hepatic 
cancer; unit 6 (the Diabetic Clinic) providing treatment 
for either Type 1 or Type 2 diabetes and; unit 7 (the 
obesity clinic) providing treatment for morbidly obese 
(BMI of 40) patients. A control group of social drinkers 
was also recruited who volunteered through a dedicated 
recruitment service based at King’s College London. The 
study was approved by the local Research Ethics 
Committee at SLaM/IOP and KCH and all subjects gave 
informed written consent.  
 
Definitions 
Subjects were recruited according to the following 
criteria:  
Social drinkers: individuals drinking ≤ 2-3 units of 
alcohol/day and who did not become intoxicated. Recruits 
would typically drink below weekly limits set at ≤14 units 
for females and ≤21 units for males and included binge 
drinkers defined as whose consuming 8 units at one time 
for males and 6 units at one time for females in a single 
session [20,21].  
Hazardous Drinkers (increased risk drinking): 
individuals drinking above safe levels but below those 
defined for harmful drinkers. This pattern of alcohol 
consumption is not a diagnostic term. 
Harmful drinkers (high-risk drinking): individuals 
drinking over the medically defined limits i.e., > 50 units 
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(400g) of alcohol/week for males and 35 units 
(280g)/week for females [22].  
Dependent drinkers: individuals who displayed a 
compulsion to drink and showed evidence of physical 
dependence (tolerance) and an inability to stop drinking 
despite harm to self [22,23]. 
 
  Drivers become high-risk drink drivers for the following 
offences:  
 
High-risk drink drivers 
Individuals convicted of two drink-driving offences 
within 10 years; driving with an alcohol concentration of 
≥ 87.5 mg/100 mL breath, 200 mg/100 mL blood, or 
267.5 mg/100 mL urine and; refusal to give a sample of 
breath, blood or urine to test for alcohol at the roadside or 
for evidential testing. 
 
Procedures 
Bespoke self-report questionnaires were designed for 
the study incorporating both tailored questions and 
standardised measures and were used for all recruitment 
units, to gather socio-demographic data, driving and drug-
use history, as well as recent alcohol consumption. Each 
subject provided measurements in order to establish the 
Body Mass Index (BMI): calculated as weight in kilograms 
divided by the square of the height in meters (kg/m2). For 
the laboratory investigations a blood sample (including 
5mL serum and 3.5mL whole blood EDTA) was collected 
from patients and from the volunteers during the day at a 
pre-specified test site. Blood samples were transported to 
KCH for routine analysis.  
 
Analysis of Biomarkers 
The following biomarkers of alcohol consumption 
were determined for all subjects using standard 
laboratory methods on the Advia 2400 analyser (Siemens 
Medical Diagnostics, Frimley, UK): GGT with assay 
imprecision being 4.4% at 31 IU/L and 1.4% at 128 IU/L 
(reference range 1-55 IU/L); AST with imprecision being 
4.9% at 58 IU/L and 4.5% at 115 IU/L (reference range 
10-50 IU/L); ALT laboratory imprecision was 3.7% at 25 
IU/L and 1.1% at 137 IU/L (reference range 5-55 IU/L); 
MCV an index of red blood cell size, reference range 79-96 
fL, was measured using the Advia 2120 analyser (Siemens 
Medical Diagnostics, UK) and %CDT was measured using 
an automated capillary electrophoresis method (Sebia 
Ltd, Camberley, UK) [7,24,25]: <2.1%CDT low alcohol 
intake, 2.2-2.9% CDT high alcohol intake, >3% CDT 
excessive alcohol intake. 
Statistical Analysis 
All data were coded and analysed using the statistical 
programme SPSS for Windows (version 22.1.4). For 
continuous data, means and standard deviations (SD) 
were presented except when the data was not normally 
distributed, in which case medians and ranges were given. 
Independent t-tests were used when comparing means 
for normally distributed continuous data, the Mann-
Whitney test was used when the distribution appeared 
skewed and 95% CI was given for the difference in means. 
For categorical data, Chi-square test was used. ANOVA, t-
tests, and chi-squared analyses were used on 
demographic and other key variables. Kruskal-Wallis 
ANOVA differences were calculated between the subject 
groups for all the analytes tested (p<0.001). We 
constructed ROC (receiver operating characteristics 
curves) curves and calculated the area under the ROC 
curve (AUC) to compare the specificity and sensitivity of 
the different biomarkers. We calculated the predictive 
value (PV) for a positive test result (PPV) that is the 
percentage of all positive results that are true positives 
and the PV for a negative result (NPV), as the percentage 
of all negative results that are true negative. Likelihood 
ratios (LRs) were used to express the odds that a given 
finding (test result) would occur in a given subject with, 
as opposed to without, a particular condition. The LR for a 
given test result is given by, LR+ve = sensitivity/ (1-
specificity) and LR-ve = specificity/(1-sensitivity). 
 
Results and Discussion 
In Table 1 the demographics for the entire study 
population are presented. 
 
Demographics 
It is well established that biomarker measurements 
are an important aid to assess recent alcohol consumption 
and are valuable for the identification of problematic 
drinking behaviour in known drinking populations [26-
29]. However, in the general population some biomarkers 
are less effective because of confounding factors, which 
affect biomarker results such as obesity, diabetes and 
hypertension: Conditions which are commonly found in 
the general population from which drink drivers emerge. 
For instance, the National Health Interview Survey in 
America in 2011 reported that 52% of adults were 
current regular drinkers, whereas based on estimates of 
body mass index, 28% were obese, 24% of adults had 
hypertension and, 9% had been diagnosed with diabetes 
[30].  
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In our study we sought to recruit participants to 
replicate a general population. A total of 408 participants 
were recruited, of which 38 were excluded (incomplete 
questionnaires or insufficient blood for analysis) leaving 
358 subjects: 165 with a diagnosis of harmful or 
dependent alcohol use currently in treatment services 
and 51 social drinkers (controls). The 358 subjects had a 
mean age of 45.7 years (range 18.7 – 81.7 years), half 
were male (53.1 %) and were mainly of white British 
ethnicity (77.9 %). Male and female subjects were 
matched for age, ethnicity (using 2 groups, black British 
and white), and BMI, if subjects from the obesity clinic 
were excluded (Table 1). The subjects also included those 
with conditions known to increase the risk of false 
positive test results with liver function tests: 142 
currently seeking treatment for liver, diabetes or obesity 
problems. 
 
Table 1: Demographics for the entire population of participants (all sites). 
Parameter Descriptor a Whole Sample – All units 
Age Years 45.7 (14.0) 
Gender 
Male (%) 190 (53.1) 
Female (%) 168 (46.9) 
Ethnicity* 
White (%) 279 (78.8) 
Black (%) 50 (14.1) 
Other (%) 25 (7.0) 
Cigarette Smokers 
Number of smokers (%) 157 (43.5) 
Mean No cigarettes per day 22.8 (15.4) 
BMI 
Mean 27.1 (9.0) 
Range 14.4-75.4 
*4 missing questionnaire responses 
*The data are expressed as the mean (SD), unless noted otherwise. 
 
Driving Behaviour 
Just over a third of the total subject population 
(38.8%) were current drivers and had car insurance 
(32.1%) although more, about half (49.2%) held a driver’s 
licence. Questions on driving offences revealed that 19% 
(n=68) of the group had at some time been banned from 
driving, and of these 31% (n=21) reported driving whilst 
banned. One third (31.6%) of our sample had been 
breathalysed between 1 and 5 times. Twenty percent of 
subjects had had a positive breath test (n = 70) and of 
these, all but 7 (90%) had been convicted of drink-driving 
(range 1-10 times); the most recent conviction occurring 
nine years previously. Of the entire sample, 30% had ever 
been in a car accident, 30 of whom reported that this 
accident was as a result of drink-driving. Over half of the 
subjects who had been in a car accident were recruited 
from the alcohol treatment populations (54%). Subjects 
from the alcohol treatment sites were significantly more 
likely to have been convicted of drink-driving (2 = 84.3, 
p<0.001); to have had an accident as the result of drink-
driving (2 = 35.6, p<0.001) and to have had a positive 
breathalyser test (2 = 82.2, p<0.001). The provision of 
education on drinking and driving to alcohol treatment 
populations is clearly an area that merits future attention.  
  
Drinking Behaviour  
A 2007 report from the North West Public Health 
Observatory (NWPHO) estimated that 1.55 million people 
in England consume alcohol at harmful levels and a 
further 6.3 million drink at hazardous levels [31]. 
Drinking behaviour across the three key populations: the 
alcohol subjects (G1), the control group of social drinkers 
(G2) and the special general hospital groups (G3) was 
significantly different as intended. Compared to the social 
drinkers and the special hospital treatment groups the 
alcohol treatment subjects drank alcohol on significantly 
more days (2 = 310.3, p<0.001) and consumed 
significantly more units of alcohol on an average day (2 = 
287.7, p <0.001) in the preceding month. The alcohol 
treatment subjects drank significantly more than the 
social drinkers; drinking on twice as many days per 
month (29.9±0.79 days out of 30, t = 7.67, p< 0.001) and 
almost 7 times as many units (36.4 ± 19.4 units/day, Z =-
10.67 p < 0.001). Within the alcohol subjects (G1) there 
was no difference in the number of days that alcohol was 
consumed in the preceding month (range 20 - 30 drinking 
days/month for each clinic). However, there was a 
significant difference in the amount (number of units) of 
alcohol consumed in an average drinking day (F = 4.7, 
p<0.01), with subjects from the inpatient units drinking 
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significantly more (42.6 ± 17.6 units/day) than those 
from the community-based units (26.7 ± 18.4 units/day). 
Within the special general hospital populations, there was 
also a significant difference between groups with the liver 
patients least likely to drink alcohol at all (F = 4.2, p<0.05) 
and the diabetes subjects drinking on significantly more 
days in the preceding month compared to the obesity 
group. 
 
 
Biomarkers of alcohol use 
Without exception each of the biomarkers was 
significantly elevated above the normal reference range in 
the alcohol treatment subjects compared to the social 
drinkers: AST and ALT (Z = -7.791, P<0.001 and Z = -
8.850, P <0.001, respectively) and; GGT (Z =-8.984, 
P<0.001). MCV was marginally raised when compared to 
the normal reference range (79-96 fL), but values were 
significantly different from the social drinkers (Table 2).  
Table 2: Comparison of the measurement of biological markers of alcohol consumption for the alcohol subjects (G1) and 
social drinkers (controls, G2) and special hospital group (G3). 
Biomarker Group Mean (SD) Median Range Test P 
AST (IU/L) 
G1 118.6 (141.3) 61.8 18 – 831 ˇ Z= -8.850 <0.001 
G2 23.9 (9.3) 21.4 14-62 
  
G3 39.3 (32.6) 28.5 10 – 220 ¨ 2 - 114.1 < 0.001 
ALT (IU/L) 
G1 68.1 (67.1) 46.7 9 – 604 ˇ Z= -7.791 <0.001 
G2 21.5 (13.9) 18 10 – 96 
  
G3 41.1 (44.2) 29.5 12 – 375 ¨2 = 78.5 <0.001 
GGT (IU/L) 
G1 405.8 (600) 157 9 – 3408 ˇ Z=-8.984 <0.001 
G2 27.3 (33.6) 18.2 6 – 190 
  
G3 91.9 (159.8) 43.5 8 – 1349 ¨2 = 117.6 <0.001 
%CDT 
G1 5.4 (3.4) 4.4 1.6 – 20.2 ˇ Z=-9.017 <0.001 
G2 2.0 (0.5) 1.84 1.2 – 3.5 
  
G3 2.1 (0.7) 1.9 1.4 – 5.4 ¨2 - 178.3 <0.001 
MCV (fL)* 
G1 96.8 (6.7) 97 68.6 – 131.5 ˇ T=9.92 <0.001 
G2 89.1 (4.1) 89.3 77.4 – 99 
  
G3 87.6 (7.2) 87.2 63.9 – 106.6 ¨F = 28.1 <0.001 
*Equal variances not assumed; ˇ Comparisons for Group 1 vs. Group 2; ¨Comparison for all groups, 1, 2 and 3. 
 
GGT is a sensitive marker of excessive alcohol 
consumption and historically widely used as an indicator 
of continuous alcohol uses [32-35], although variability in 
the response to alcohol use has been recognised more 
recently [36]. We found plasma GGT activity was 
significantly raised (Z=-8.984, P<0.001) in G1-alcohol 
treatment subjects (except out-patient unit 4) compared 
to the control group of social drinkers (G2). However, GGT 
is a non-specific indicator of liver damage and cannot 
differentiate between liver disease originating from 
alcohol or non-alcohol-related origins. Accordingly, we 
observed participants with acute and chronic hepatitis 
and pancreatitis had elevated GGT concentrations 
(median GGT 75.5 IU/L). 
 
The validity of GGT in the identification of continuous 
drinking in a general population has long-since been 
queried because of confounding conditions such as when 
patients are prescribed anticonvulsant drugs, due to 
enzyme induction [37]. False positive results for GGT have 
also been linked to obesity, hypertension, Type 2 diabetes 
and signs of steatosis [38,39]. GGT concentrations in our 
obesity clinic subjects (mean BMI >48.9) and in the 
diabetic clinic where some subjects were obese (mean 
BMI 31.4) were within the normal range, although GTT 
concentrations were elevated in the overweight subjects 
from the liver clinic (mean BMI 27.1), but this was likely 
influenced by non-alcoholic liver disease. 
 
GGT values were significantly elevated above the 
normal reference range in the alcohol dependent subjects 
(inpatient Unit 1, mean 477 IU/L and Unit 2 mean 477 
IU/L respectively; and community-based Unit 3 mean 122 
IU/L and unit 4 mean 326 IU/L). They were also raised in 
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the Liver clinic (mean 165 IU/L). Figure 1 (Box Blot 1) 
shows GGT concentrations were significantly higher than 
the median from the diabetic and obesity subjects and the 
median GGT for the social drinkers (controls) was 
significantly lower than that of any of the other groups. In 
Figure 1 (Box Plot 2) the median %CDT was increased in 
the drinking treatment populations (Inpatient unit 1, 
mean 6.0 %CDT, unit 2, mean 5.1 and the community-
based unit 3, mean 6.4 %CDT) but was within the normal 
reference range for all other participants. 
 
 
Figure 1: GGT and %CDT results across the different 
sub populations.  
 
 
 
Figure 1: Box Plot 1 and 2 visualises the results for 
GGT and %CDT across the different sub populations, 
respectively:  denotes outliers,  denotes the mean 
and standard deviation, ‡ multiple results, …… denotes 
subjects outside the 25th or 75th inter quartile range, 
the box denotes the median and the lower (25th ) and 
upper (75th ) inter quartile range. 
Key: AAU, unit 2; AH1, unit 1; BER, unit 3; DIAB, 
Diabetes clinic; LIV, Liver clinic; OBS, Obesity clinic; 
SIG, unit 4 and; VOL, social drinkers (control group) 
 
 
Our results indicate that MCV as a biomarker of 
continued drinking was poor (0.57) when compared to 
GGT (0.73) and %CDT (0.76). These findings confirmed 
earlier work that highlighted the high risk of false positive 
findings with this biomarker, although more recent 
research suggest alcohol metabolic genotypes may play a 
role in its performance [40,41]. MCV was found to have 
good specificity (0.96) for the identification of an alcohol 
use disorder when the alcohol treatment and the social 
drinking groups were compared. Our findings suggest 
that MCV cannot be recommended as a sole primary 
screening test for high risk drink-drivers. It is noteworthy 
that MCV had a positive predictive value of 0.83 and 
should be seen as complementary to %CDT, particularly 
for female populations. 
  
AST was significantly raised above the reference range 
in our participants recruited from G1-alcohol treatment 
subjects (except out-patient unit 4) but was within 
normal ranges for the control group of social drinkers 
(G2) and the special general hospital groups (G3). This 
was predicted: AST is present in cytosolic and 
mitochondrial forms whilst ALT is cytosolic and alcohol is 
believed to result in functional damage to hepatic 
mitochondria [42]. Aminotransferase elevations are 
frequently the first finding in hepatocellular reactions to 
drugs and toxic agents. Indeed AST tends to be raised in 
drug users (especially those who use crack cocaine) due 
to underlying muscle myopathy [43]. The use of crack 
cocaine may well have been a contributing factor for the 
high AST (73.0 IU/L) value reported for Unit 2 
participants and could be an important confounder in 
young male high risk drivers. Both ALT and AST were 
elevated with increased alcohol consumption but these 
biomarkers did not demonstrate sufficient sensitivity 
(0.42 and 0.59) to be used as sole indicators of continuous 
drinking.  
 
Research suggests that %CDT is a potentially valuable 
tool to use in alcohol treatment and problematic drinking 
in adolescents. It has been recently suggested as an 
effective monitoring tool to indicate changes over time in 
binge drinking [44]. In our study, %CDT concentrations in 
the alcohol treatment groups was significantly higher 
compared to the other sub-groups (Z=-9.017, p<0.001) 
reflecting excessive alcohol intake (%CDT >3 %), (Table 
2).  
 
Predictive value 
The predictive value (PV) was used to determine how 
each biomarker would perform in our participants 
(selected to represent a normal general population from 
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which high-risk drink driver emerge). The risk of false 
positive test results (positive predictive value (+ve PPV)) 
was comparable for %CDT (negative predictive value (+ve 
PPV), 0.98) and GGT (+ ve PPV 0.95). Similarly, the 
percentage of all negative results that were true negatives 
for %CDT and GGT (-ve PPV 0.41 versus –ve PPV 0.54) 
were alike (Table 3).  
 
Table 3, 3a, 3b: Comparison of the sensitivity and specificity of different biomarkers in identifying alcohol consumption: 
in the alcohol treatment groups (G1) and the social drinkers (control) (G2). In Table 3a, the whole population, G1, G2, and 
G3 combined, and in Table 3b, in the alcohol treatment groups (G1) and the specialist general hospital groups (liver, 
obesity and diabetes) (G3). 
Biochemical Test Sensitivity Specificity Positive Predictive Value Negative Predictive Value LR +VE LR-VE 
AST 0.59 0.94 0.97 0.42 10.1 0.43 
ALT 0.42 0.96 0.97 0.34 0.97 0.34 
GGT 0.73 0.92 0.95 0.54 6.49 0.22 
%CDT 0.76 0.88 0.98 0.41 14.55 0.45 
MCV 0.55 0.96 0.98 0.41 13.81 0.47 
Table 3a 
AST 0.59 0.85 0.78 0.71 4.09 0.47 
ALT 0.42 0.89 0.75 0.64 3.65 0.66 
GGT 0.73 0.69 0.67 0.75 2.38 0.39 
%CDT 0.76 0.88 0.85 0.81 6.41 0.27 
MCV 0.57 0.9 0.83 0.71 5.62 0.48 
Table 3b 
AST 0.59 0.82 0.8 0.64 3.37 0.49 
ALT 0.42 0.86 0.77 0.56 2.96 0.68 
GGT 0.73 0.61 0.69 0.66 1.88 0.43 
%CDT 0.76 0.88 0.88 0.76 6.38 0.27 
Predictive value (PV) is the ability of a test to identify a specific condition depends on the prevalence of the condition in 
the population being studied. PPV+ve, the PV for a positive result, is the percentage of all positive results that are true 
positives and PPV-ve, the PV for a negative result, is the percentage of all negative results that are true negatives. 
Likelihood ratio’s (LRs) used to express the odds that a given finding (test result) would occur in a given subject with, as 
opposed to without, a particular condition. The LR for a given result is given by LR+ve = sensitivity/(1- specificity) and LR-ve 
= specificity /(1- sensitivity) 
 
However, when the whole population was considered 
(G1, G2 and G3) %CDT exhibited the same diagnostic 
power across all groups whereas GGT showed a distinct 
fall in specificity and positive predictive value (Table 3a). 
Additionally, when comparing the alcohol treatment sub-
population groups with the special general hospital sub-
populations (liver, diabetes and obesity), %CDT exhibited 
the same diagnostic power, whereas GGT showed a 
distinct fall in specificity (0.88 vs. 0.61) and positive 
predictive value (+ve PPV 0.95 vs. +ve PPV 0.69) (Table 
3b). An important apparent benefit of %CDT is that the 
percentage of false positives was relatively low (high 
specificity) compared to other biomarkers. %CDT 
retained diagnostic power when used as an indicator of 
alcohol consumption against the whole subject population 
(+ve PPV = 0.85 for %CDT vs 0.67 for GGT). In recent 
years, %CDT has been recognised as a reliable state 
marker of high alcohol consumption [45]. We have shown 
that %CDT would be suitable for the medical examiner 
tasked with the need to confirm ‘fitness-to-drive’ in a 
high-risk drink-driving offender.  
  
Sensitivity and specificity 
The specificity and sensitivity of a biomarker is crucial 
particularly when used to aid assessment as part of the 
process leading to a decision to reinstate driving 
entitlement at the end of the disqualification period for 
those drink-drivers whose conviction places them within 
the high risk offender category: those drink-drivers who 
are thought to pose a particularly high risk to other road 
users. 
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When the G1-alcohol subjects were pooled with G3-
the special general hospital groups there was little 
difference in the sensitivity or the specificity of %CDT and 
GGT tests (0.76 vs 0.73% and 0.88 vs 0.92%), 
respectively. Our findings indicate that the sensitivity and 
the specificity of GGT activity for the identification of 
excessive alcohol consumption are good in circumstances 
where the status of the drinker is known. The sensitivity 
of GGT was 0.73 (%CDT 0.76) and specificity was 0.92 
(%CDT 0.88) when G1 treatment population was 
compared to G2 social drinkers. However, when the two 
tests were compared against our whole sample 
population the diagnostic power of GGT was significantly 
reduced with specificity falling for GGT to 0.69 (0.88 for 
%CDT): thus in a high risk drinking populations where 
liver disease, obesity and diabetes are common [46] the 
specificity of GGT to detect chronic heavy drinking may be 
reduced. 
 
The AUC of a ROC curve confirmed the greater 
sensitivity and specificity of %CDT when compared to 
GGT for the detection of excessive alcohol consumption 
within a population consisting of subjects with different 
drinking behaviours and medical conditions. The ROC 
curve was constructed using the full data set from all 
population groups, which included the diabetic and obese 
subjects and was synonymous with those observed in 
high-risk drink-driving populations. The sensitivity and 
specificity of %CDT for the diagnosis of excessive alcohol 
consumption was 0.91 (AUC), whereas the diagnostic 
power of GGT was poorer (area under curve 0.80) as 
shown in Figure 2. 
 
We have confirmed the high specificity of %CDT but 
this is quite well established, whereas its sensitivity has 
been less well defined. In our study %CDT was able to 
identify drinking indicative of excessive alcohol intake (>3 
%CDT) significantly more accurately than other 
biomarkers (Z=-9.017, p<0.001). The greater diagnostic 
power of %CDT was seen when data was combined from 
the whole sample set (G1, G2 and G3). The sensitivity and 
specificity of %CDT for the diagnosis of excessive alcohol 
use remained unchanged (AUC 0.91) whereas the 
diagnostic power of GGT was poorer (AUC 0.80).  
 
 
 
Figure 2: Receiver Operating Characteristic (ROC) Curve showing the Area Under the Curve (AUC) for GGT, %CDT, 
MCV, AST and ALT comparing the identification of continuous drinking using data from the whole sample set (G1, G2, 
and G3). 
 
 
The test result variable(s): GGT, %CDT, MCV, AST, ALT 
have at least one tie between the positive actual state 
group and the negative actual state group: a) Under the 
nonparametric assumption, b) Null hypothesis: true area 
= 0.5. AUC (Std error, asymptotic 95% CI): GGT 0.798 
(0.024, 0.751-0.845); %CDT 0.906 (0.016, 0.875-0.937); 
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MCV 0.848 (0.021, 0.807-0.889); AST 0.803 (0.023, 0.757-
0.849); ALT 0.723 (0.028, 0.669-0.777). 
 
 Conclusion 
This study was carried out to determine if the 
diagnostic efficacy (sensitivity and specificity) of %CDT 
was suitable for the detection of continued alcohol 
consumption in high-risk drink drive offenders. Our 
findings demonstrate that %CDT provides an objective 
tool for more accurate decision making and contributing 
to the evidence based practices in road safety. %CDT is a 
better diagnostic tool in populations where confounders 
for common biomarkers of alcohol consumption are 
present.  
 
Recommendations 
 %CDT may be used to assess drivers for relicensing 
purposes since elevated %CDT is not confounded by 
common medical and life-style factors that confound 
other biomarkers. 
 %CDT provides an effective sole marker for recent 
alcohol use in banned drink-drivers wishing to return 
to driving, because of the higher positive predictive 
value compared to other biomarkers.  
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